Log in to search using one of your social media accounts:

 

Glatopa (glatiramer acetate Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 19, 2017 Category: Drugs & Pharmacology Source Type: news

Digital: Teaching An Old Dog New Tricks?
This year ’s eyeforpharma Barcelona conference made me feel old.Firstly, while chatting with [eyeforpharma Chairman] Paul Simms, I realized I have attended all but one or two since their inception. Secondly, there was a lot of discussion about digital topics and I can ’t even use Facebook correctly.Ironically, I was asked to chair the last day ’s discussion – on digital transformation. An old dog leading a discussion about new tricks.Recognizing my own ineptitude, I turned to someone who really knows about digital transformation – my son. My older son joined Tesla last year, working as a digit...
Source: EyeForPharma - March 20, 2017 Category: Pharmaceuticals Authors: Kevin Dolgin Source Type: news

Copaxone (Glatiramer Acetate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 6, 2017 Category: Drugs & Pharmacology Source Type: news

Mylan wins court ruling for Copaxone 40mg/mL patents
Global generic and specialist pharmaceuticals company Mylan has won a US District Court Ruling with regards to its Copaxone 40mg/mL patents. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 1, 2017 Category: Pharmaceuticals Source Type: news

Court invalidates 4 Teva patents for MS drug
The U.S. District Court in Delaware ruled four of Teva Pharmaceutical Industries Ltd.'s patents for Copaxone were invalid, dealing Teva its latest setback in the company's efforts to ward off generic competition for its top revenue-producing product. The ruling sent Teva's stock price down nearly 8 percent to $31.81 per share in pre-market trading Tuesday morning. “We intend to move forward with an immediate appeal,” said Erez Vigodman, Teva's president and CEO. “We will continue to vigorously… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 31, 2017 Category: Pharmaceuticals Authors: John George Source Type: news

US Court rules in favour of Mylan for Copaxone patents: Natco
In December 2016, the US Patent and Trademark Office (PTO) had ruled in favour of Mylan and three patents related to Copaxone 40 mg/mL were found unpatentable. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 31, 2017 Category: Pharmaceuticals Source Type: news

U.S. court rejects Teva's patent-infringement claims on Copaxone
(Reuters) - Teva Pharmaceutical Industries Ltd said on Monday a U.S. court rejected four of the Israel-based drugmaker's claims of patent infringement on its top-selling multiple sclerosis treatment. (Source: Reuters: Health)
Source: Reuters: Health - January 31, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Teva provides financial forecast – with a caveat
Teva Pharmaceutical Industries Ltd. provided analysts Friday with its projections for revenues and earnings in 2017, but included a caveat with its numbers. The generic drug giant said it expects revenues in the $23.8 billion to $24.5 billion range, and operating income of between $7.4 billion and $7.8 billion. Those numbers assume its Copaxone, the company’s branded multiple sclerosis drug, does not face generic competition in the United States thi s year. Teva expects sales of Copaxone, its top… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 6, 2017 Category: Biotechnology Authors: John George Source Type: news

Third U.S. patent on Teva's MS drug Copaxone invalidated
NEW YORK (Reuters) - U.S. patent officials on Thursday invalidated a third patent covering Teva Pharmaceutical Industries' $4 billion multiple sclerosis treatment Copaxone, after cancelling two other patents on the drug last week. (Source: Reuters: Health)
Source: Reuters: Health - September 1, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

What Genetics are Associated with Multiple Sclerosis?
Discussion Multiple sclerosis (MS) is “a chronic degenerative, often episodic disease of the central nervous system marked by patchy destruction of the myelin that surrounds and insulates nerve fibers, usually appearing in young adulthood and manifested by one or more mild to severe neural and muscular impairments, as spastic weakness in one or more limbs, local sensory losses, bladder dysfunction, or visual disturbances.” It is a chronic disease and therefore symptoms must occur more than once. The first episode is called an acute demyelinating attack. Fifteen to forty-five percent of children with their first...
Source: PediatricEducation.org - April 4, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Blood-borne biomarkers of MS relapse identified
NEW ORLEANS – Three potentially useful blood-based biomarkers of relapse and of the response to glatiramer acetate treatment have been identified in patients with relapsing-remitting multiple... (Source: Clinical Neurology News)
Source: Clinical Neurology News - February 24, 2016 Category: Neurology Source Type: news

Designing to Succeed
The finalists for this year’s Most Valuable Patient Initiative or Service at the 2016 eyeforpharma Barcelona Awards showcase the potential for impact when patients become collaborators in design. Understanding the human aspects of living with a condition is in many ways less straightforward than drug development. Everyone experiences their health challenges differently, and it’s clear this can’t be designed for in a lab. That’s why collaborating with the patient brings benefits. Here are three lessons we learned from this year’s crop of patient innovators:  1. Ongoing engagement with the ...
Source: EyeForPharma - February 10, 2016 Category: Pharmaceuticals Authors: Thomas Disley Source Type: news

Should We Encourage the 'Old' Therapies for MS?Should We Encourage the 'Old' Therapies for MS?
Would patients with RRMS do better by continuing with interferon beta or glatiramer acetate treatment over the long-term, instead of switching to a newer therapeutic regimine? Journal of Neurology, Neurosurgery, and Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2015 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

Novartis: Alcon reorg on tap for 2016
(Reuters) — Novartis (NYSE:NVS) has agreed in principle to pay $390 million to settle U.S. allegations that it used kickbacks to speciality pharmacies to push sales of some drugs, the Swiss company said today, hitting 3rd-quarter earnings. The U.S. Justice Dept. had sued Novartis in a Manhattan federal court, saying the world’s biggest seller of prescription drugs sought illegally to boost sales of drugs covered by Medicare and Medicaid. The $390 million settlement, still pending approval, pushed Novartis’s 3rd-quarter net income down 42% to $1.8 billion. Novartis’s underlying re...
Source: Mass Device - October 27, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Legal News MassDevice Earnings Roundup Optical/Ophthalmic Source Type: news

New Glatiramer Acetate Generic 'Equivalent' to Copaxone in MSNew Glatiramer Acetate Generic 'Equivalent' to Copaxone in MS
The GATE study, showing equivalence of the generic to the branded drug, should pave the way for the first generic of a disease-modifying treatment for multiple sclerosis in the European market. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 20, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Generic Glatiramer Matches Branded Copaxone in Clinical Efficacy (CME/CE)
(MedPage Today) -- But don't expect a break from the high annual cost (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 14, 2015 Category: Neurology Source Type: news

Teva’s Copaxone gets Japanese approval for multiple sclerosis relapse prevention
The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for Israel-based Teva Pharmaceutical Industries' once-daily Copaxone (glatiramer acetate injection) 20mg injection for prevention of multiple sclerosis relapse. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 29, 2015 Category: Pharmaceuticals Source Type: news

Teva Announces Approval of COPAXONE(R) in Japan for the Prevention of Relapse of Multiple Sclerosis
JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) announced today the approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) of once-daily COPAXONE® (glatiramer acetate injection... Biopharmaceuticals, Neurology, RegulatoryTeva Pharmaceutical, COPAXONE, glatiramer, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 28, 2015 Category: Pharmaceuticals Source Type: news

Teva's MS drug Copaxone has strong second-quarter sales
JERUSALEM (Reuters) - Teva Pharmaceutical Industries , which this week revealed plans to buy Allergan's generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition. (Source: Reuters: Health)
Source: Reuters: Health - July 30, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Alcon’s sluggish Q2 hits Novartis
(Reuters) — A weak performance from eyecare division Alcon, plus the strong dollar, hit Novartis (NYSE:NVS) in the 2nd quarter, scuppering hopes that the Swiss drugmaker would raise its 2015 financial outlook. The difficulties at Alcon reflected lower sales of contact lenses, intraocular lenses and surgical equipment, offsetting a solid showing in pharmaceuticals and an impressive sales jump within the Sandoz generics business. With overall quarterly core net income falling short of expectations, Novartis lowered its full-year sales forecast for Alcon and raised guidance for Sandoz. The unchanged overall ou...
Source: Mass Device - July 21, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: MassDevice Earnings Roundup Optical/Ophthalmic Alcon Inc. Novartis AG Source Type: news

First generic multiple sclerosis drug, made in Cambridge, launches
Cambridge-based Momenta Pharmaceuticals and partner Sandoz announced plans late yesterday to launch the first generic drug in the U.S. to treat multiple sclerosis, priced 15 percent less than the branded version of the drug. Momenta (Nasdaq: MNTA) developed the generic of the 20 milligram dosage of Copaxone, a once-a-day injectable drug by Israel-based Teva Pharmaceuticals (Nasdaq: TEVA) that generated $4.2 billion in revenue last year. The Cambridge biotech has partnered with Sandoz, the generics… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 19, 2015 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

US court finds Teva's Copaxone patent invalid again: Natco Pharma
Natco Pharma, a city-based drug maker, today said the US Court of Appeals for Federal Court has again found one of the patents of Teva's Copaxone as invalid. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 19, 2015 Category: Pharmaceuticals Source Type: news

Novartis’ Sandoz introduces generic version of Teva’s multiple sclerosis drug
Novartis subsidiary Sandoz has introduced Glatopa in the US, a generic version of Teva's Copaxone (glatiramer acetate injection) 20mg/ml one-time-daily multiple sclerosis (MS) therapy. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 18, 2015 Category: Pharmaceuticals Source Type: news

Novartis’s Sandoz introduces generic version of Teva’s multiple sclerosis drug
Novartis subsidiary Sandoz has introduced Glatopa in the US, a generic version of Teva's Copaxone (glatiramer acetate injection) 20mg/ml one-time-daily multiple sclerosis (MS) therapy. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 18, 2015 Category: Pharmaceuticals Source Type: news

U.S. appeals court again invalidates Teva's MS drug patent
NEW YORK (Reuters) - A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version. (Source: Reuters: Health)
Source: Reuters: Health - June 18, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Glatiramer Acetate Industry in Global & Chinese Regions Forecast...
ReportsnReports.com adds “2015 Glatiramer Acetate Industry Report – Global and Chinese Market Scenario” to its store.(PRWeb May 21, 2015)Read the full story at http://www.prweb.com/releases/glatiramer-acetate-market/global-and-chinese-2020/prweb12739431.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 21, 2015 Category: Pharmaceuticals Source Type: news

Glatopa (glatiramer acetate injection) for the Treatment of Multiple Sclerosis
Glatopa (glatiramer acetate injection, formerly M356) is the first substitutable generic drug approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). (Source: Drug Development Technology)
Source: Drug Development Technology - May 11, 2015 Category: Pharmaceuticals Source Type: news

Glatopa (glatiramer acetate Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 5, 2015 Category: Drugs & Pharmacology Source Type: news

Study shows MS drugs are cost effective
The six year data from the ten year Risk-sharing Scheme project has found that the beta interferon drugs and glatiramer acetate are cost effective treatments for the NHS. People taking one of these drugs showed a slower increase in EDSS measures than predicted for untreated controls. Pharmaceutical Journal Risk-sharing Scheme (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 23, 2015 Category: Neurology Source Type: news

Less frequent glatiramer acetate (Copaxone)
People who took the three times a week version of Copaxone for three years did better than those who were in the placebo group for the first year of the trial. Presented at the American Academy of Neurology (AAN) meeting. MPR Glatiramer acetate (Copaxone) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 22, 2015 Category: Neurology Source Type: news

Generic drugmaker Teva makes $40 billion offer for rival Mylan
TEL AVIV/NEW YORK (Reuters) - Teva Pharmaceutical Industries Ltd on Tuesday made an unsolicited $40 billion offer for smaller rival Mylan NV, a bold bid for growth as its lucrative Copaxone drug faces generic competition. (Source: Reuters: Health)
Source: Reuters: Health - April 21, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Teva shares slide on generic Copaxone fears
TEL AVIV (Reuters) - Teva Pharmaceutical Industries shares slid five percent on Sunday after U.S. regulators approved a generic version of its top-selling multiple sclerosis drug and amid reports it was mulling a bid for rival Mylan. (Source: Reuters: Health)
Source: Reuters: Health - April 19, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Generic Version of Copaxone, Multiple Sclerosis Drug, Is Approved
Ten drugs are now approved to treat multiple sclerosis but none of them has had a generic equivalent. It is possible that the introduction of the generic Copaxone could help keep prices of all the drugs in check. (Source: NYT Health)
Source: NYT Health - April 16, 2015 Category: Consumer Health News Authors: ANDREW POLLACK Tags: Drugs (Pharmaceuticals) Sandoz International GmbH Food and Drug Administration Teva Pharmaceutical Industries Ltd TEVA NASDAQ Novartis AG NVS NYSE Momenta Pharmaceuticals Inc MNTA NASDAQ Multiple Sclerosis Generic Brands and Products Mylan Source Type: news

FDA Approves First Generic Copaxone in Multiple SclerosisFDA Approves First Generic Copaxone in Multiple Sclerosis
A generic version of the standard MS therapy glatiramer acetate receives FDA approval. FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 16, 2015 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news

Sandoz Grabs FDA Approval for Generic of Teva's Copaxone
The FDA has approved the first generic version of Teva's top branded product, multiple sclerosis drug Copaxone. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 16, 2015 Category: Pharmaceuticals Source Type: news

FDA Greenlights First Copaxone Generic
(MedPage Today) -- FDA approves generic glatiramer acetate despite efforts by Teva to stave off competition. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 16, 2015 Category: American Health Source Type: news

Generic Copaxone Approved for Multiple Sclerosis
Autoimmune disease affects central nervous systemSource: HealthDay Related MedlinePlus Pages: Medicines, Multiple Sclerosis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 16, 2015 Category: Consumer Health News Source Type: news

FDA approves first generic Copaxone to treat multiple sclerosis
The U.S. Food and Drug Administration today approved the first generic version of Copaxone (glatiramer acetate injection), used to treat patients with relapsing forms of multiple sclerosis (MS). (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 16, 2015 Category: American Health Source Type: news

Generic Copaxone approved in US
The FDA - the US drug regulator - has approved Glatopa, a generic version of glatiramer acetate, taken as a daily injection. The drug is unlikely to be marketed in the US until later in the year. FDA MedPage Today Glatiramer acetate - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 15, 2015 Category: Neurology Source Type: news

Positive interim results from major UK study on MS drugs
Results of the analysis of the 6 year data of the Department of Health (DH) MS Risk-sharing Scheme (RSS), published in the Lancet Neurology today, show that the disease modifying drugs Avonex, Betaferon, Copaxone and Rebif are cost effective and are clinically effective in reducing the progression of the disease in people with relapsing remitting multiple sclerosis (MS). (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 1, 2015 Category: Neurology Source Type: news

Setback to Natco pharma; US Supreme Court sends Teva patent case to Federal Circuit
The US Supreme Court has sent back the patent case related to Teva's multiple sclerosis drug Copaxone for a review by the Federal Circuit. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 22, 2015 Category: Pharmaceuticals Source Type: news

Supreme Court Sides with Teva on Drug Patent
The U.S. Supreme Court ruled that Teva Pharmaceutical Industries still has patent protection for top-selling multiple sclerosis drug Copaxone. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 21, 2015 Category: Pharmaceuticals Source Type: news

Supreme Court sides with Teva in MS drug patent dispute
The U.S. Supreme Court reversed a lower court ruling that had invalidated a patent held by Teva Pharmaceuticals for its multiple sclerosis drug Copaxone. Teva (NYSE: TEVA) has spent several years in court attempting to fend off generic competition for Copaxone, which generates annual sales of about $4 billion for the company. The company is based in Israel and has its U.S. headquarters in North Wales, Pa. Copaxone is approved for use in reducing the frequency of relapses in patients with the relapsing… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 20, 2015 Category: Biotechnology Authors: John George Source Type: news

Supreme Court rules for Teva over MS drug patent
WASHINGTON (Reuters) - The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. (Source: Reuters: Health)
Source: Reuters: Health - January 20, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Beta interferon and Copaxone relapse rates similar
A study has found that over 10 years the relapse rate for people on glatiramer acetate or beta interferon is similar. MS Discovery Forum Disease modifying drugs for relapsing remitting MS - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - January 20, 2015 Category: Neurology Source Type: news

Teva optimistic U.S. top court to rule in favor of MS drug patent
TEL AVIV (Reuters) - Teva Pharmaceutical Industries is optimistic the U.S. Supreme Court will decide in its favor regarding patent protection for Copaxone, its multiple sclerosis treatment, Chief Executive Erez Vigodman said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - October 30, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Beta-Interferon, Glatiramer Acetate Cost-Effective in MSBeta-Interferon, Glatiramer Acetate Cost-Effective in MS
A new analysis from the UK has suggested that both beta-interferon and glatiramer acetate delay disability and are cost-effective for the long-term treatment of multiple sclerosis. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 19, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

ACTRIMS/ECTRIMS Summary
A review of some of the research from the recent ACTRIMS/ECTRIMSconference, including daclizumab, generic glatiramer acetate, a fingolimod similar, body temperature, cholesterol, comorbidities, stem cells, cognition, genetics, vitamin D and diet. National MS Society (USA) Latest MS research updates (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - September 16, 2014 Category: Neurology Source Type: news

Generic GA Shows Equivalence on MRI Endpoints in MSGeneric GA Shows Equivalence on MRI Endpoints in MS
A generic version of the MS drug glatiramer acetate looked similar to the branded product (Copaxone) in terms of reduction in MRI lesions and side effects in the GATE study. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 13, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news